CY1107092T1 - USE OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF EMOTIONAL DISEASES - Google Patents

USE OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF EMOTIONAL DISEASES

Info

Publication number
CY1107092T1
CY1107092T1 CY20071101592T CY071101592T CY1107092T1 CY 1107092 T1 CY1107092 T1 CY 1107092T1 CY 20071101592 T CY20071101592 T CY 20071101592T CY 071101592 T CY071101592 T CY 071101592T CY 1107092 T1 CY1107092 T1 CY 1107092T1
Authority
CY
Cyprus
Prior art keywords
treatment
glycosaminoglycans
anxiety
emotional
emotional diseases
Prior art date
Application number
CY20071101592T
Other languages
Greek (el)
Inventor
Umberto Cornelli
Ambrosi Luigi De
Stanley Lorens
Jawed Fareed
John Lee
Original Assignee
Umberto Cornelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04741606A external-priority patent/EP1631298B8/en
Application filed by Umberto Cornelli filed Critical Umberto Cornelli
Publication of CY1107092T1 publication Critical patent/CY1107092T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Η παρούσα εφεύρεση εξετάζει τη χρήση κλασμάτων γλυκοζαμινογλυκάνης με μέσο μοριακό βάρος 2400 (V200) D για την παρασκευή φαρμακευτικών συνθέσεων κατάλληλων για τη θεραπεία συναισθηματικών δυσλειτουργιών και, ειδικότερα, για διαταραχές κατάθλιψης, διαταραχές άγχους, αγχώδη νεύρωση, ανησυχία, σύγχυση.The present invention contemplates the use of glycosaminoglycan fractions with an average molecular weight of 2400 (V200) D for the preparation of pharmaceutical compositions suitable for the treatment of emotional dysfunctions and, in particular, for depression disorders, anxiety disorders, anxiety, anxiety.

CY20071101592T 2003-05-21 2007-12-14 USE OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF EMOTIONAL DISEASES CY1107092T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI200310123 2003-05-21
EP04741606A EP1631298B8 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treating emotional dysfunctions

Publications (1)

Publication Number Publication Date
CY1107092T1 true CY1107092T1 (en) 2012-10-24

Family

ID=49231655

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101592T CY1107092T1 (en) 2003-05-21 2007-12-14 USE OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF EMOTIONAL DISEASES

Country Status (1)

Country Link
CY (1) CY1107092T1 (en)

Similar Documents

Publication Publication Date Title
CY1117476T1 (en) SUPPLEMENTARY COMPETITORS AND THEIR USES
LTPA2017009I1 (en) Bruton tyrosine kinase inhibitors
CR20110245A (en) MUTANTS FGF21 AND USE OF THE SAME.
CY1106476T1 (en) SUBSTITUTED DIHYDROQUINAZOLINES WITH ANTIVIRAL PROPERTIES
CY1115580T1 (en) COMPOSITION AND ANTI-VIVAL ACTIVITY OF SUBSTITUTED AZAIDOLOLOXIC Piperazine Derivatives
ATE448232T1 (en) SUBSTITUTED HETEROCYCLES
FR13C0062I2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR TREATING NEUROLOGICAL DISORDERS
BRPI0912411A2 (en) use of a human interleukin-2 mutein (hil-2 mutein) or a fragment thereof, pharmaceutical composition for the treatment and / or prophylaxis of an autoimmune disease, use of human interleukin-2 mutein (hil-2 mutein) 2) or a section thereof, for the formation of regulatory t cells (treg) in an organism, method for treatment and / or prophylaxis of an autoimmune disease in an organism, method for formation of regulatory t cells (treg) in an organism organism, method for formation of regulatory t cells (treg) in vitro.
BR0214309A (en) Substituted aryl-1,4-pyrazine derivatives
ECSP045081A (en) DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
DE60326859D1 (en) DRUGS ADMINISTRATION
UY26249A1 (en) SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES LAW 17164 ART. 127
CY1110199T1 (en) PHARMACEUTICAL COMPOSITIONS OF A NEUROACTIVE STEROID AND THEIR USES
BR9907189A (en) Products of the lipid fraction of the sea cucumber carotenoid and methods of use
BRPI0606112A2 (en) 3 - heteroaryl - 3 - hydroxy - 2 - amino - propyl amines and related compounds, as well as their use and pharmaceutical composition
UY27755A1 (en) NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS.
ATE508114T1 (en) ISOINDOLYL COMPOUNDS SUBSTITUTED WITH N-ALKYLHYDROXAMIC ACIDS AND THEIR PHARMACEUTICAL USE
CY1117499T1 (en) 5'-TRIPHOSPHORIC OLIGONUCLEOTIDE WITH HELD TYPE AND USES
CY1115384T1 (en) ANTI-INFLAMMATIVE COMPOSITION
HRP20090336T1 (en) Antitumor combinations containing vegf - trap and 5fu or one of its derivatives
BRPI0410467A (en) compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
CY1108953T1 (en) PHARMACEUTICAL FORM INCLUDING PYRIMIDINES A1 PRODUCT COATED WITH INTERMEDIATE POLYMERS
CY1114811T1 (en) NEW FRACTIONS OF PROTEIN MILK AND THEIR USE FOR PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
CY1112121T1 (en) Derivatives of 1,2,3,4-tetrahydropyrrolo- [1,2-a] -pyrazine-6-carboxamides and 2,3,4,5-tetrahydropyrrolo- (1,2-a) -diazepine-7-carbamide , THEIR PREPARATION AND THEIR APPLICATION TO THERAPEUTIC EDUCATION
DK1220852T3 (en) Substituted diazepanes